M4K-2009

• Description:

  M4K-2009 is an BBB-penetrant inhibitor of ALK2 with an IC50 of 13 nM. M4K-2009 is an analogue of LDN-214117 (HY-16712) . M4K-2009 is also active against the hERG potassium channel[1][2][3].

• UNSPSC:

  12352005

• Target:

  TGF-β Receptor

• Related Pathways:

  TGF-beta/Smad

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Smiles:

  COC(C=C1C2=CN=CC(C3=CC=C(N4CCNCC4)C=C3)=C2C)=C(C(OC)=C1)OC

• Molecular Formula:

  C25H29N3O3

• Molecular Weight:

  419.52

• References & Citations:

  [1]González-Álvarez, H., et al., (2024) . Discovery of Conformationally Constrained ALK2 Inhibitors. Journal of medicinal chemistry, 67 (6), 4707-4725. |[2]Ensan, D., (2020) . Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma. Journal of medicinal chemistry, 63 (9), 4978-4996.|[3]Smil, D., (2020) . Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma. Journal of medicinal chemistry, 63 (17), 10061-10085.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2600795-07-9]